Undiscovered Gems In India Featuring 3 Promising Small Caps
In This Article:
Over the last 7 days, the Indian market has dropped 1.1%, but it has risen by an impressive 41% over the past year, with earnings expected to grow by 17% per annum in the coming years. In this dynamic environment, identifying promising small-cap stocks can be a strategic move for investors looking to capitalize on growth opportunities.
Top 10 Undiscovered Gems With Strong Fundamentals In India
| Name | Debt To Equity | Revenue Growth | Earnings Growth | Health Rating |
|---|---|---|---|---|
| Bharat Rasayan | 8.15% | 0.10% | -7.93% | ★★★★★★ |
| NGL Fine-Chem | 12.95% | 15.22% | 8.68% | ★★★★★★ |
| AGI Infra | 61.29% | 29.13% | 33.44% | ★★★★★★ |
| Knowledge Marine & Engineering Works | 35.48% | 46.55% | 46.96% | ★★★★★★ |
| TCPL Packaging | 95.84% | 15.51% | 31.89% | ★★★★★☆ |
| Kalyani Investment | NA | 21.42% | 6.35% | ★★★★★☆ |
| Magadh Sugar & Energy | 85.41% | 6.65% | 13.60% | ★★★★☆☆ |
| Sky Gold | 127.01% | 22.02% | 48.03% | ★★★★☆☆ |
| Apollo Micro Systems | 38.51% | 10.59% | 11.93% | ★★★★☆☆ |
| SG Mart | 16.77% | 98.09% | 96.54% | ★★★★☆☆ |
We'll examine a selection from our screener results.
Gallantt Ispat
Simply Wall St Value Rating: ★★★★★☆
Overview: Gallantt Ispat Limited manufactures iron and steel in India and internationally, with a market cap of ?86.89 billion.
Operations: Gallantt Ispat Limited generates revenue primarily through the manufacture and sale of iron and steel products. The company has a market cap of ?86.89 billion.
Gallantt Ispat, a promising player in the metals and mining sector, has seen its debt to equity ratio rise from 8.1% to 18.8% over five years, yet it remains satisfactory at 16.6%. Recent earnings growth of 115.2% outpaces industry averages, reflecting robust performance with net income hitting INR 1.22 billion for Q1 2024 compared to INR 307 million last year. With a P/E ratio of 27.5x below the market average and EBIT covering interest payments by a factor of 16.8x, Gallantt presents an attractive investment case amidst rising revenues and high-quality earnings.
-
Delve into the full analysis health report here for a deeper understanding of Gallantt Ispat.
-
Examine Gallantt Ispat's past performance report to understand how it has performed in the past.
Marksans Pharma
Simply Wall St Value Rating: ★★★★★★
Overview: Marksans Pharma Limited, along with its subsidiaries, is involved in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ?97.13 billion.
Operations: Marksans Pharma generates revenue through the sale of generic pharmaceutical formulations globally. The company has a market cap of ?97.13 billion.